28 November 2024
Prostate Cancer Foundation of Australia is standing up to call for earlier, faster and fairer access to new medicines for Australian men and families impacted by cancer.
People in all corners of our great country often have to wait more than 442 days for reimbursed access to registered medicines required to treat their disease.
As a member of the Bridging Funding Coalition we unreservedly endorse the Coalition’s National Consensus Statement to bridge the funding gap between TGA registration and listing on the PBS.
We are calling on the Federal Government to establish an Expert Implementation Group to help us deliver accessible and affordable health care for all.
About bridging funding
Bridging funding is a form of temporary funding that enables eligible Australian patients to access medicines at the time of Therapeutic Goods Administration (TGA) registration, where the medicine is an improvement in treatment – providing high added therapeutic value OR addresses high unmet clinical need.
The option for bridging funding will be designed to help more Australians access medicines who may have received a prognosis where they need access to time-critical treatment, where there are no other equivalent options.
Our partners include NeuroEndocrine Cancer Australia, Peter MacCallum Cancer Centre, PCPA, Arrotex Pharmaceuticals, So Brave, Lung Foundation Australia, Rare Cancers Australia, GSK, IQVIA, Inherited Cancer Australia, MOGA, AGITG, Icon Group, Leukaemia Foundation, Omico and AstraZeneca.
For more information or for support, phone PCFA on 1800 22 00 99 or check out our Survivorship Toolkit.
